The transplanted liver graft is capable of clearing asymmetric dimethylarginine

Asymmetric dimethylarginine (ADMA) has been recognized as an endogenous inhibitor of the arginine–nitric oxide (NO) pathway. Its concentration is tightly regulated by urinary excretion and degradation by the enzyme dimethylarginine dimethylaminohydrolase (DDAH), which is highly expressed in the liver. Considering the liver as a crucial organ in the clearing of ADMA, we hypothesized increased ADMA levels during hepatic failure and, consequently, a decline of ADMA concentrations after successful liver transplantation. The aim of the present study was to investigate the role of the liver in the metabolism of ADMA in patients undergoing liver transplantation. In this prospective study, we investigated the course of ADMA concentrations in 42 patients undergoing liver transplantation and results showed that preoperative ADMA concentrations were higher in patients with acute (1.26 μmol/L, P < .001) and in patients with chronic (.69 μmol/L, P < .001) hepatic failure compared with healthy volunteers (.41 μmol/L). In addition, ADMA concentrations decreased from the preoperative day to the first postoperative day in both the acute (ΔADMA: −.63 μmol/L, P = .005) and the chronic hepatic failure group (ΔADMA: −0.15 μmol/L, P < .001). Furthermore, in patients who experienced acute rejection, ADMA concentrations were higher during the whole first postoperative month compared with nonrejectors (P = .012). Moreover, in 11 of 13 rejectors (85%) a clear increase in ADMA concentration preceded the onset of the first episode of rejection, which was confirmed by liver biopsy. In conclusion, our results indicate that the transplanted liver graft is quickly capable of clearing ADMA, suggesting preservation of DDAH. In addition, increased ADMA concentrations in the posttransplantation period reflect serious dysfunction of the liver graft during acute rejection. (Liver Transpl 2004;10:1524–1530.)

[1]  H. Prins,et al.  Handling of asymmetrical dimethylarginine and symmetrical dimethylarginine by the rat kidney under basal conditions and during endotoxaemia. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[2]  R. Böger.  The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. , 2003, Cardiovascular research.

[3]  H. Prins,et al.  Handling of asymmetrical dimethylarginine (ADMA) and symmetrical dimethylarginine (SDMA) by the rat kidney under basal conditions and endotoxemia , 2003 .

[4]  T. Teerlink,et al.  Asymmetrical dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality , 2003, Clinical nutrition.

[5]  R. Nijveldt,et al.  The liver is an important organ in the metabolism of asymmetrical dimethylarginine (ADMA). , 2003, Clinical nutrition.

[6]  N. A. Callejas,et al.  Presence of methylated arginine derivatives in orthotopic human liver transplantation: Relevance for liver function , 2003, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[7]  C. Stehouwer,et al.  Net renal extraction of asymmetrical (ADMA) and symmetrical (SDMA) dimethylarginine in fasting humans. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[8]  D. Geller,et al.  Blockade of the L‐arginine/NO synthase pathway worsens hepatic apoptosis and liver transplant preservation injury , 2002, Hepatology.

[9]  P. Tsao,et al.  Impaired Nitric Oxide Synthase Pathway in Diabetes Mellitus: Role of Asymmetric Dimethylarginine and Dimethylarginine Dimethylaminohydrolase , 2002, Circulation.

[10]  R. Nijveldt,et al.  Determination of arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography. , 2002, Analytical biochemistry.

[11]  C. Zoccali,et al.  Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study , 2001, The Lancet.

[12]  Wolfgang Knecht,et al.  Structure of the Bacillus subtilis D-aminopeptidase DppA reveals a novel self-compartmentalizing protease , 2001, Nature Structural Biology.

[13]  P. Tsao,et al.  Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. , 1999, Circulation.

[14]  S. Bode-Böger,et al.  Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. , 1999, Journal of the American Society of Nephrology : JASN.

[15]  A. Tanaka,et al.  Liver-type arginase in serum during and after liver transplantation: a novel index in monitoring conditions of the liver graft and its clinical significance. , 1998, Clinica chimica acta; international journal of clinical chemistry.

[16]  S. Clarke,et al.  RNA and protein interactions modulated by protein arginine methylation. , 1998, Progress in nucleic acid research and molecular biology.

[17]  K. Katzarski,et al.  Serum levels of NG, NG-dimethyl-L-arginine, a potential endogenous nitric oxide inhibitor in dialysis patients. , 1997, Journal of the American Society of Nephrology : JASN.

[18]  Randall G. Lee,et al.  Banff schema for grading liver allograft rejection: An international consensus document , 1997, Hepatology.

[19]  U. Förstermann,et al.  Interference of L-arginine analogues with L-arginine transport mediated by the y+ carrier hCAT-2B. , 1997, Nitric oxide : biology and chemistry.

[20]  M. Kimoto,et al.  Detection of NG,NGDimethylarginine Dimethylaminohydrolase in Human Tissues Using a Monoclonal Antibody , 1995 .

[21]  M. Kimoto,et al.  Detection of NG,NG-dimethylarginine dimethylaminohydrolase in human tissues using a monoclonal antibody. , 1995, Journal of biochemistry.

[22]  E. Roth,et al.  L-Arginine deficiency after liver transplantation as an effect of arginase efflux from the graft. Influence on nitric oxide metabolism. , 1994, Transplantation.

[23]  D. Aswad,et al.  Peptides with sequences similar to glycine, arginine-rich motifs in proteins interacting with RNA are efficiently recognized by methyltransferase(s) modifying arginine in numerous proteins. , 1993, The Journal of biological chemistry.

[24]  M. Kimoto,et al.  Detection of NG,NG-dimethylarginine dimethylaminohydrolase in the nitric oxide-generating systems of rats using monoclonal antibody. , 1993, Archives of biochemistry and biophysics.

[25]  S. Moncada,et al.  Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure , 1992, The Lancet.

[26]  A. Beaudet,et al.  Mammalian urea cycle enzymes. , 1986, Annual review of genetics.

[27]  P. Carnegie,et al.  Urinary excretion of methylarginine in human disease. , 1977, Metabolism: clinical and experimental.

[28]  Y. Kakimoto,et al.  Isolation and Identification of Ng,Ng- and Ng,N'g-Dimethylarginine, Nε-Mono-, Di-, and Trimethyllysine, and Glucosylgalactosyl- and Galactosyl-δ-hydroxylysine from Human Urine , 1970 .

[29]  Y. Kakimoto,et al.  Isolation and identification of N-G,N-G- and N-G,N'-G-dimethyl-arginine, N-epsilon-mono-, di-, and trimethyllysine, and glucosylgalactosyl- and galactosyl-delta-hydroxylysine from human urine. , 1970, The Journal of biological chemistry.